GlaxoSmithKline’s Alli
GSK has recently announced that Alli, a 60-milligram diet pill, is now available in Europe.
The pharmaceutical company has obtained a non-prescription license for the drug and it is the first time for any non-prescription medicine to receive approval from the European Commission. The license grants approval for GSK to recommend Alli for adults with a Body Mass Index of 28kg/m2 or more when taken with a decreased calorie, reduced-fat diet.
The president of GlaxoSmithKline Consumer Healthcare in Europe said that Alli provides adults with a chance to lose weight and millions of people in the United States have acknowledged it. He further expressed his excitement about the extension of the product to Europe, which will help people counter obesity.
Alli is clinically tested and proven. When taken with the proper reduced-calorie diet, it can aid people in losing weight for about 50% more compared to simple dieting. It functions by breaking off some of the person’s fat that is absorbed into the body.
Alli is an added category in weight loss aid that receives support through pharmacy preparation, a behavioral support program in various European countries, and a multi-million pound investment in concentrated on customer advertising. The circulation of the non-prescription drug is exclusive through pharmacies.